Tumor necrosis factor-α and the development of multiple organ failure

[1]  E. Vollmer,et al.  The role of tumor necrosis factor in the development of multiple organ failure in a murine model , 2000, Critical care medicine.

[2]  S. Nasraway,et al.  Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock , 1998, The Lancet.

[3]  E. Deitch.  ANIMAL MODELS OF SEPSIS AND SHOCK: A REVIEW AND LESSONS LEARNED , 1998, Shock.

[4]  S. Targan,et al.  A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .

[5]  E. Tindall,et al.  Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. , 1997, The New England journal of medicine.

[6]  A. Baue.  Multiple organ failure, multiple organ dysfunction syndrome, and systemic inflammatory response syndrome. Why no magic bullets? , 1997, Archives of surgery.

[7]  K. Asadullah,et al.  Monocyte deactivation in septic patients: Restoration by IFN-γ treatment , 1997, Nature Medicine.

[8]  H. Bruining,et al.  p55 Tumor Necrosis Factor Receptor Fusion Protein in the Treatment of Patients With Severe Sepsis and Septic Shock: A Randomized Controlled Multicenter Trial , 1997 .

[9]  J. Bland,et al.  Plasma proinflammatory cytokine concentrations, Acute Physiology and Chronic Health Evaluation (APACHE) III scores and survival in patients in an intensive care unit. , 1996, Critical care medicine.

[10]  R. Bone,et al.  Sir Isaac Newton, sepsis, SIRS, and CARS. , 1996, Critical care medicine.

[11]  R. Goris,et al.  Inflammatory cytokines in an experimental model for the multiple organ dysfunction syndrome. , 1996, Critical care medicine.

[12]  S. Opal,et al.  Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. , 1996, The New England journal of medicine.

[13]  F. Schildberg,et al.  Downregulation of proinflammatory cytokine release in whole blood from septic patients. , 1995, Blood.

[14]  J. Devière,et al.  Interleukin-10 production during septicaemia , 1994, The Lancet.

[15]  Kevin J. Tracey,et al.  Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia , 1987, Nature.

[16]  J. D. Albert,et al.  Shock and tissue injury induced by recombinant human cachectin. , 1986, Science.

[17]  R. Goris,et al.  Multiple-organ failure and sepsis without bacteria. An experimental model. , 1986, Archives of surgery.

[18]  B. Beutler,et al.  Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. , 1985, Science.

[19]  B. Beutler,et al.  Identity of tumour necrosis factor and the macrophage-secreted factor cachectin , 1985, Nature.